HC Wainwright Research Analysts Lower Earnings Estimates for Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Analysts at HC Wainwright decreased their Q1 2024 EPS estimates for shares of Reviva Pharmaceuticals in a research note issued to investors on Monday, April 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.28) for the quarter, down from their prior forecast of ($0.27). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q3 2024 earnings at ($0.24) EPS, Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.04) EPS and FY2025 earnings at ($1.09) EPS.

Separately, Benchmark reissued a “speculative buy” rating and set a $17.00 price target on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 16th.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ RVPH opened at $3.02 on Wednesday. Reviva Pharmaceuticals has a 1 year low of $2.67 and a 1 year high of $9.25. The stock has a market cap of $84.32 million, a P/E ratio of -1.84 and a beta of -0.02. The firm has a 50-day moving average of $3.57 and a 200 day moving average of $4.10.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Armistice Capital LLC raised its holdings in Reviva Pharmaceuticals by 194.0% in the fourth quarter. Armistice Capital LLC now owns 1,764,000 shares of the company’s stock worth $9,085,000 after buying an additional 1,164,000 shares during the last quarter. EMC Capital Management raised its holdings in shares of Reviva Pharmaceuticals by 1,294.3% during the third quarter. EMC Capital Management now owns 123,915 shares of the company’s stock valued at $613,000 after purchasing an additional 115,028 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in shares of Reviva Pharmaceuticals during the fourth quarter valued at approximately $72,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.